A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1 –2 Oral Anti-Diabetic Drugs

ConclusionOverall, once-weekly semaglutide 1.0  mg as an add-on to 1–2 OADs is the most efficacious GLP-1 RA in terms of the reduction of HbA1c and weight from baseline after 6  months of treatment. In addition, the analysis suggests that once-weekly semaglutide is well tolerated and not associated with an increase in discontinuations due to AEs compared with other GLP-1 RAs.FundingNovo Nordisk.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research